Evidence map›Paper›PMID 38456959›Full record

ArticleMolecular biotechnology2025

O-sialoglycoprotein Endopeptidase (OSGEP) Suppresses Hepatic Ischemia-Reperfusion Injury-Induced Ferroptosis Through Modulating the MEK/ERK Signaling Pathway.

Yuanyuan Tao, Wanqing Zhou, Cheng Chen, Qian Zhang, Zhuoyi Liu, Pingping Xia, Zhi Ye, Chunling Li

Abstract read
In one paragraph

Article in Molecular biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yuanyuan Tao *Department of Anesthesiology, Xiangya Hospital of Central South University, Hunan Province, Changsha, 410008, China.
Wanqing Zhou *Department of Anesthesiology, Xiangya Hospital of Central South University, Hunan Province, Changsha, 410008, China.
Cheng ChenDepartment of Anesthesiology, Xiangya Hospital of Central South University, Hunan Province, Changsha, 410008, China.
Qian ZhangDepartment of Anesthesiology, Xiangya Hospital of Central South University, Hunan Province, Changsha, 410008, China.
Zhuoyi LiuDepartment of Anesthesiology, Xiangya Hospital of Central South University, Hunan Province, Changsha, 410008, China.
Pingping XiaDepartment of Anesthesiology, Xiangya Hospital of Central South University, Hunan Province, Changsha, 410008, China.
Zhi YeDepartment of Anesthesiology, Xiangya Hospital of Central South University, Hunan Province, Changsha, 410008, China.
Chunling LiDepartment of Anesthesiology, Xiangya Hospital of Central South University, Hunan Province, Changsha, 410008, China. liclane7413@hotmail.com.ORCID http://orcid.org/0000-0002-7678-0926

Funding

National Natural Science Foundation of China 82001393National Natural Science Foundation of China 82171467Natural Science Foundation of Hunan Province 2021JJ3119
6 · The paper itself

Abstract

Hepatic ischemia-reperfusion injury (HIRI) was widely accepted as a critical complication of liver resection and transplantation. A growing body of evidence suggested that O-sialoglycoprotein endopeptidase (OSGEP) was involved in cell proliferation and mitochondrial metabolism. However, whether OSGEP could mediate the pathogenesis of HIRI has still remained unclarified. This study investigated whether OSGEP could be protective against HIRI and elucidated the potential mechanisms. The OSGEP expression level was detected in cases undergoing ischemia-related hepatectomy and a stable oxygen-glucose deprivation/reoxygenation (OGD/R) condition in hepG2 cells. Additionally, it was attempted to establish a mouse model of HIRI, thus, the function and mechanism of OSGEP could be analyzed. At one day after hepatectomy, the negative association of OSGEP expression level with the elevated serum levels of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) was noted. Moreover, it was attempted to carry out gain- and loss-of-function analyses of OSGEP in hepG2 cells to reveal its influences on OGD/R-induced injury and relevant signaling pathways. The findings suggested that OSGEP overexpression significantly protected hepG2 cells against ferroptotic cell death, while OSGEP consumption had opposite effects. Consistent with in vitro studies, OSGEP deficiency exacerbated liver functions and ferroptotic cell death in a mouse model of HIRI. The results also revealed that OSGEP mediated the progression of HIRI by regulating the MEK/ERK signaling pathway. Rescue experiments indicated that ERK1/2 knockdown or overexpression reversed the effects of OSGEP overexpression or knockdown on hepG2 cells under OGD/R condition. Taken together, the findings demonstrated that OSGEP could contribute to alleviate HIRI by mediating the MEK-ERK signaling pathway, which may serve as a potential prognostic marker and a therapeutic target for HIRI.

Indexed as

MAP Kinase Signaling SystemReperfusion InjuryAnimalsDisease Models, AnimalEndopeptidasesFemaleHep G2 CellsHumansLiverMaleMiceMice, Inbred C57BLMiddle AgedEndopeptidasesFerroptosishepatic ischemia–reperfusion injury (HIRI)MEK1/2-ERK1/2 signaling pathwayO-sialoglycoprotein endopeptidase (OSGEP)

Identifiers

PMID38456959
PMCPMC11711258

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.